Your move, Roche: what next for crenezumab in Alzheimer's?
This article was originally published in Scrip
Executive Summary
Genentech/Roche's and AC Immune's anti-amyloid antibody crenezumab has missed its endpoints in two Phase II trials but not badly enough to write the product off just yet.